Clinical Trials Logo

EBV-associated Malignancies clinical trials

View clinical trials related to EBV-associated Malignancies.

Filter by:
  • None
  • Page 1

NCT ID: NCT03988582 Withdrawn - Clinical trials for EBV-associated Malignancies

Safety and Effectiveness of EBV-specific Cytotoxic T Cells for the Treatment for EBV Lymphomas or Other EBV-associated Malignancies

Start date: June 11, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test whether treatment with EBV-specific cytotoxic T cells (EBV-CTLs) is effective, and to test any good and bad effects of treatment with EBV-CTLs. EBV-CTLs are a special immune cells that may attack abnormal cells. EBV-CTLs are made by taking cells from a healthy person, growing them in a laboratory for several weeks to educate them to recognize and destroy EBV infected cells, and then storing them in a freezer until they are required for treatment.

NCT ID: NCT01498484 Completed - Clinical trials for EBV-associated Malignancies

Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

Start date: December 2011
Phase: Phase 2
Study type: Interventional

This is a Phase II trial to evaluate the efficacy and safety of human leukocyte antigen (HLA) partially-matched third-party allogeneic Epstein-Barr virus cytotoxic T lymphocytes (EBV-CTLs) for the treatment of EBV-induced lymphomas and EBV-associated malignancies.

NCT ID: NCT00002663 Completed - Clinical trials for EBV-associated Malignancies

Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

Start date: March 1995
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.